PDS Biotech's Abstract Accepted for ESMO Congress 2024

PRINCETON, N.J., Aug. 05, 2024 – PDS Biotechnology Corporation (Nasdaq: PDSB), a company at the forefront of immunotherapy innovations, has announced that updated data from its VERSATILE-002 trial will be showcased at the European Society for Medical Oncology (ESMO) Congress 2024. The congress is scheduled to take place from September 13-17, 2024, in Barcelona, Spain.

The VERSATILE-002 trial examines the efficacy of the Versamune® HPV therapeutic vaccine, formerly known as PDS0101, when used in conjunction with KEYTRUDA® (pembrolizumab). This combination is being tested as a first-line treatment for patients with HPV16-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The abstract detailing these findings has been accepted for presentation, highlighting significant progress in this area of cancer treatment.

The poster presentation, listed as number 879P, is titled "VERSATILE-002: Survival with First-Line Treatment with PDS0101 Therapeutic Vaccine and Pembrolizumab in HPV16-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)". The presenting author is Dr. Jared Weiss, a prominent figure in oncology, who serves as the Section Chief of Thoracic and Head/Neck Oncology and a Professor of Medicine at the University of North Carolina. Dr. Weiss is also the Principal Investigator for the VERSATILE-002 clinical trial.

PDS Biotechnology is a company dedicated to revolutionizing the treatment of cancers and the development of vaccines for infectious diseases through its innovative immunotherapy platforms. In 2024, the company plans to initiate a pivotal clinical trial aimed at advancing its lead program for treating advanced HPV16-positive head and neck squamous cell cancers. 

Their leading investigational immunotherapy, Versamune® HPV, is being developed in two primary combinations. The first is with a standard-of-care immune checkpoint inhibitor, and the second is a triple combination that includes PDS01ADC, an IL-12 fused antibody drug conjugate, in addition to the immune checkpoint inhibitor. These combinations are designed to enhance the immune system's ability to target and destroy cancer cells more effectively.

PDS Biotechnology continues to focus on harnessing the power of the immune system to provide innovative solutions for cancer treatment. Their ongoing research and development efforts are aimed at bringing these promising treatments to patients who need them the most, potentially transforming the landscape of cancer therapy.

The acceptance of their VERSATILE-002 trial data for presentation at a prestigious event like the ESMO Congress underscores the significance of their work and the potential impact it could have on cancer treatment protocols. As the company moves forward with its clinical trials and research initiatives, PDS Biotechnology remains committed to advancing medical science and improving outcomes for patients with difficult-to-treat cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!